The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies
Conclusion Despite treatment with novel agents for RRMM in 86% of patients, an outcome gap persists for older patients and those with RI and/or CVD. Personalized treatment approaches that account for age and comorbidities, and further evaluation of innovative regimens and dosing schedules, are needed to improve outcomes for these patients.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Cardiology | Cardiovascular | Databases & Libraries | Electronic Medical Records (EMR) | Geriatrics | Heart | Myeloma | Study